Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study

BACKGROUND: Venetoclax is a selective, potent inhibitor of the anti-apoptotic B-cell leukemia/lymphoma-2 protein approved for treatment of chronic lymphocytic leukemia. We conducted a dose-finding study of venetoclax in combination with bendamustine–rituximab (BR) in patients with relapsed/refractor...

Descripción completa

Detalles Bibliográficos
Autores principales: de Vos, S, Swinnen, L J, Wang, D, Reid, E, Fowler, N, Cordero, J, Dunbar, M, Enschede, S H, Nolan, C, Petrich, A M, Ross, J A, Salem, A H, Verdugo, M, Agarwal, S, Zhou, L, Kozloff, M, Nastoupil, L J, Flowers, C R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158762/
https://www.ncbi.nlm.nih.gov/pubmed/30060083
http://dx.doi.org/10.1093/annonc/mdy256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158762/
https://www.ncbi.nlm.nih.gov/pubmed/30060083
http://dx.doi.org/10.1093/annonc/mdy256

Ejemplares similares